← All trials
NCT04286789
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 29, 2020
- Primary completion
- Jun 30, 2020
- Completion date
- Jul 31, 2020
- First posted
- Feb 27, 2020
- Last posted
- Feb 27, 2020
- Enrollment
- 16
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Oryn Therapeutics, LLCLead sponsor
- University of Southern CaliforniaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.